Recent News

• 08.14.2025 - MiNK Therapeutics Second Quarter 2025 Financial Results
• 08.14.2025 - MiNK Therapeutics Second Quarter 2025 Financial Results
• 08.14.2025 - MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
• 08.14.2025 - MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
• 07.31.2025 - MiNK Therapeutics to Provide Corporate Update and Second Quarter 2025 Financial Report
• 07.31.2025 - MiNK Therapeutics to Provide Corporate Update and Second Quarter 2025 Financial Report
• 07.15.2025 - MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
• 07.15.2025 - MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
• 07.11.2025 - MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
• 07.11.2025 - MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

Recent Filings

• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.14.2025 - EX-99.1 EX-99.1
• 07.15.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.15.2025 - 8-K Current report
• 07.14.2025 - 8-K Current report
• 06.18.2025 - 8-K Current report